Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1948 1
1950 1
1951 3
1952 1
1953 1
1958 2
1964 1
1965 3
1966 2
1967 1
1968 2
1969 5
1970 3
1971 1
1972 3
1973 2
1974 1
1975 7
1976 2
1977 3
1979 1
1980 1
1983 1
1984 1
1985 1
1986 4
1987 1
1988 1
1989 2
1990 4
1991 3
1992 3
1993 2
1994 3
1997 3
1998 2
1999 1
2000 1
2001 5
2002 4
2003 8
2004 2
2005 7
2006 6
2007 5
2008 6
2009 8
2010 10
2011 9
2012 15
2013 16
2014 16
2015 16
2016 20
2017 33
2018 19
2019 17
2020 13
2021 13
2022 9
Text availability
Article attribute
Article type
Publication date

Search Results

304 results
Results by year
Filters applied: . Clear all
Page 1
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE. Chebib FT, et al. Among authors: chapman ab. J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. doi: 10.1681/ASN.2018060590. Epub 2018 Sep 18. J Am Soc Nephrol. 2018. PMID: 30228150 Free PMC article. Review.
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators. Torres VE, et al. Among authors: chapman ab. N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4. N Engl J Med. 2017. PMID: 29105594 Free article. Clinical Trial.
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. Among authors: chapman ab. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121377 Free PMC article. Clinical Trial.
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC; Conference Participants. Chapman AB, et al. Kidney Int. 2015 Jul;88(1):17-27. doi: 10.1038/ki.2015.59. Epub 2015 Mar 18. Kidney Int. 2015. PMID: 25786098 Free PMC article.
Blood pressure in early autosomal dominant polycystic kidney disease.
Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB; HALT-PKD Trial Investigators. Schrier RW, et al. Among authors: chapman ab. N Engl J Med. 2014 Dec 11;371(24):2255-66. doi: 10.1056/NEJMoa1402685. Epub 2014 Nov 15. N Engl J Med. 2014. PMID: 25399733 Free PMC article. Clinical Trial.
Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome.
Chertow GM, Appel GB, Andreoli S, Bangalore S, Block GA, Chapman AB, Chin MP, Gibson KL, Goldsberry A, Iijima K, Inker LA, Knebelmann B, Mariani LH, Meyer CJ, Nozu K, O'Grady M, Silva AL, Stenvinkel P, Torra R, Warady BA, Pergola PE. Chertow GM, et al. Among authors: chapman ab. Am J Nephrol. 2021;52(3):180-189. doi: 10.1159/000513777. Epub 2021 Mar 31. Am J Nephrol. 2021. PMID: 33789284 Free PMC article. Clinical Trial.
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease.
Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, Bennett WM, Meyers CM, Walker DL, Bae K, Zhang QJ, Thompson PA, Miller JP, Harris PC; CRISP Consortium. Rossetti S, et al. Among authors: chapman ab. J Am Soc Nephrol. 2007 Jul;18(7):2143-60. doi: 10.1681/ASN.2006121387. Epub 2007 Jun 20. J Am Soc Nephrol. 2007. PMID: 17582161 Free article.
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators. Torres VE, et al. Among authors: chapman ab. Nephrol Dial Transplant. 2018 Mar 1;33(3):477-489. doi: 10.1093/ndt/gfx043. Nephrol Dial Transplant. 2018. PMID: 28379536 Free PMC article. Clinical Trial.
Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.
Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE; CRISP Investigators. Irazabal MV, et al. Among authors: chapman ab. J Am Soc Nephrol. 2015 Jan;26(1):160-72. doi: 10.1681/ASN.2013101138. Epub 2014 Jun 5. J Am Soc Nephrol. 2015. PMID: 24904092 Free PMC article.
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. Among authors: chapman ab. Clin J Am Soc Nephrol. 2016 May 6;11(5):803-11. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23. Clin J Am Soc Nephrol. 2016. PMID: 26912543 Free PMC article. Clinical Trial.
304 results